Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 9,104,294 shares of Aura Biosciences, Inc. common stock, including 4,464,294 shares issuable upon exercise of warrants, representing 8.44% of Aura’s common stock.
The ownership percentage is calculated based on 103,436,416 shares of common stock outstanding as of June 12, 2026, and assumes exercise of the warrants held by Adage Capital Partners, L.P. The Reporting Persons share voting and dispositive power over these securities and disclaim that the filing alone constitutes an admission of beneficial ownership.
Positive
None.
Negative
None.
Key Figures
Beneficially owned shares:9,104,294 sharesOwnership percentage:8.44%Shares outstanding baseline:103,436,416 shares+3 more
6 metrics
Beneficially owned shares9,104,294 sharesTotal Aura Biosciences common stock beneficially owned by the Reporting Persons
Ownership percentage8.44%Percentage of Aura Biosciences common stock beneficially owned, assuming warrant exercise
Shares outstanding baseline103,436,416 sharesAura Biosciences common stock outstanding as of June 12, 2026, per Definitive Proxy Statement
Shares issuable via warrants4,464,294 sharesCommon shares issuable upon exercise of warrants held by Adage Capital Partners, L.P.
Shared voting power9,104,294 sharesShares over which each Reporting Person has shared voting power
Shared dispositive power9,104,294 sharesShares over which each Reporting Person has shared dispositive power
"The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerfinancial
"6 | Shared Voting Power 9,104,294.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"8 | Shared Dispositive Power 9,104,294.00"
warrantsfinancial
"Includes 4,464,294 shares of Common Stock issuable upon exercise of warrants"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
investment managerfinancial
"ACM, as the investment manager of Adage Capital Partners, L.P."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Aura Biosciences (AURA) does Adage Capital report owning?
Adage Capital and related Reporting Persons report beneficial ownership of 8.44% of Aura Biosciences’ common stock. This is based on 103,436,416 shares outstanding as of June 12, 2026, and assumes exercise of certain warrants.
How many Aura Biosciences (AURA) shares are reported as beneficially owned?
The Reporting Persons disclose beneficial ownership of 9,104,294 shares of Aura Biosciences common stock. This total includes both currently held shares and shares issuable upon exercise of warrants held by Adage Capital Partners, L.P.
How many Aura Biosciences (AURA) shares are tied to warrants in this filing?
The filing states that 4,464,294 shares of Aura Biosciences common stock are issuable upon exercise of warrants held by Adage Capital Partners, L.P., and these are included in the total reported beneficial ownership.
What share count did the AURA ownership percentage rely on?
The 8.44% ownership figure is calculated using 103,436,416 shares of Aura Biosciences common stock outstanding as of June 12, 2026, as reported in Aura’s Definitive Proxy Statement on Schedule 14A filed June 29, 2026.
Who are the Reporting Persons in the Aura Biosciences (AURA) Schedule 13G/A?
The Reporting Persons are Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. Adage Capital acts as investment manager to Adage Capital Partners, L.P., which directly holds Aura shares and related warrants.
Do the Reporting Persons share voting and dispositive power over AURA shares?
Yes. The cover pages indicate 0 shares with sole voting or dispositive power and 9,104,294 shares with shared voting and shared dispositive power for each Reporting Person in relation to Aura Biosciences’ common stock.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
Aura Biosciences, Inc.
(Name of Issuer)
Common Stock, par value $0.00001 per share
(Title of Class of Securities)
05153U107
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
05153U107
1
Names of Reporting Persons
Adage Capital Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,104,294.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,104,294.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,104,294.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.44 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: Includes 4,464,294 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.
SCHEDULE 13G
CUSIP Number(s):
05153U107
1
Names of Reporting Persons
Robert Atchinson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,104,294.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,104,294.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,104,294.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.44 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: Includes 4,464,294 shares of Common Stock issuable upon exercise of warrants.
SCHEDULE 13G
CUSIP Number(s):
05153U107
1
Names of Reporting Persons
Phillip Gross
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
9,104,294.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9,104,294.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
9,104,294.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.44 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: Includes 4,464,294 shares of Common Stock issuable upon exercise of warrants.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Aura Biosciences, Inc.
(b)
Address of issuer's principal executive offices:
80 Guest Street, Boston, Massachusetts 02135
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"), with respect to the common stock, par value $0.00001 per share ("Common Stock") of Aura Biosciences, Inc., a Delaware corporation (the "Company"), and shares of Common Stock issuable upon exercise of warrants directly held by ACP;
(ii) Robert Atchinson ("Mr. Atchinson"), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), general partner of ACP, and (2) managing member of Adage Capital Partners, L.L.C., a Delaware limited liability company ("ACPLLC"), general partner of ACM, with respect to the Common Stock and shares of Common Stock issuable upon exercise of warrants directly held by ACP; and
(iii) Phillip Gross ("Mr. Gross"), as (1) managing member of ACA, managing member of ACPGP, and (2) managing member of ACPLLC, general partner of ACM, with respect to the Common Stock and shares of Common Stock issuable upon exercise of warrants directly held by ACP.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
(c)
Citizenship:
ACM is a limited partnership organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.
(d)
Title of class of securities:
Common Stock, par value $0.00001 per share
(e)
CUSIP No.:
05153U107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 103,436,416 shares of Common Stock outstanding as of June 12, 2026, as reported in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 29, 2026, and assumes the exercise of the warrants held by ACP.
(b)
Percent of class:
8.44%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Adage Capital Management, L.P.
Signature:
/s/ Robert Atchinson
Name/Title:
By: Adage Capital Partners, L.L.C., its General Partner, By: Robert Atchinson, its Managing Member
